Statement of Changes in Beneficial Ownership (4)
November 04 2019 - 4:21PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
REICIN ALISE |
2. Issuer Name and Ticker or Trading Symbol
CELGENE CORP /DE/
[
CELG
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) PRES., GLOBAL CLINICAL DEV.
|
(Last)
(First)
(Middle)
C/O CELGENE CORPORATION, 86 MORRIS AVENUE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/1/2019
|
(Street)
SUMMIT, NJ 07901
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
11/1/2019
|
|
M
|
|
11903
|
A
|
$0 (1)(2)
|
11903
|
D
|
|
Common Stock
|
11/1/2019
|
|
F
|
|
4722
|
D
|
$108.53
|
7181
|
D
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code (Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)
|
8. Price of Derivative Security (Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Restricted Stock Unit
|
(1)(2)
|
11/1/2019
|
|
M
|
|
|
11903
|
(1)
|
(1)
|
Common Stock
|
11903
|
$0 (3)
|
23807 (4)
|
D
|
|
Explanation of Responses:
|
(1)
|
One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock.
|
(2)
|
Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
|
(3)
|
The restricted stock units were issued pursuant to the Company's 2014 Equity Incentive Plan.
|
(4)
|
The remainder of the restricted stock units will vest in two installments as follows: 11,903 shares on November 1,2020 and 11,904 shares on November 1, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
REICIN ALISE C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT, NJ 07901
|
|
|
PRES., GLOBAL CLINICAL DEV.
|
|
Signatures
|
/s/ Jonathan Biller, Attorney-in-Fact
|
|
11/4/2019
|
**Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person, see Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Dec 2023 to Dec 2024
See More Message Board Posts
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.